Shi-Yuan Cheng, PhD, professor in The Ken and Ruth Davee Department of Neurology in the Division of Neuro-oncology, has been named a fellow of the American Association for the Advancement of Science (AAAS) for his outstanding contributions to molecular and translational cancer research.
Year: 2020
In late March, the world came to a virtual standstill. The COVID-19 pandemic forced leaders around the world to limit large gatherings and shutter schools and businesses. For Feinberg’s research enterprise, this was a serious disruption — but science kept moving forward.
A new Northwestern Medicine study has identified tissue-specific epigenetic regulators in zebrafish, filling in a longtime gap in the understanding of the organism’s genome.
Second-year medical students Jeff Clark, Nathan Shlobin, and Steven Hoffman are the co-authors of a first of its kind study, which found that more than 80 percent of patients hospitalized with COVID-19 experienced neurological manifestations.
The presence of inflammatory proteins was associated with comorbidity burden and deteriorating heart function in patients with heart failure with preserved ejection fraction, according to a Northwestern Medicine study.
A new residency mentorship program developed by Northwestern faculty may serve as a model for other academic programs seeking to provide more formalized mentorship opportunities for residents.
Mutations in PCM1, a gene involved in the formation of cilia, were linked with schizophrenia in a variety of animal models and in human genome analysis, according to a recent study.
The Northwestern University Clinical and Translational Sciences (NUCATS) Institute hosted the first virtual COVID-19 symposium, which gave the Northwestern research community an opportunity to learn about efforts to advance public health and respond to the COVID-19 pandemic.
Northwestern scientists have determined how two protein mutations responsible for the impaired motor function in Parkinson’s disease independently disrupt neuron activity.
Combining the current standard-of-care chemotherapy drug with a genetic inhibitor may improve treatment for pancreatic ductal adenocarcinoma, according to a recent study published in PNAS.